In October 2024, Virios Therapeutics merged with Wex Pharmaceuticals, Inc. to form Dogwood Therapeutics, Inc. (DWTX). Virios' common stock stopped trading under the VIRI symbol and began trading under the DWTX symbol on the Nasdaq Capital Market on October 9, 2024.
- Virios Therapeutics is a biotechnology company that develops antiviral therapies for diseases like fibromyalgia and Long-COVID.
- Wex Pharmaceuticals is a private biopharmaceutical company that develops non-opioid analgesics.
- Dogwood Therapeutics will focus on developing Halneuron, IMC-1, and IMC-2.
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is a late‐stage drug development company dedicated to the development, manufacture, and commercialization of innovative drug products to treat pain. WEX is a leader in research in the field of sodium channel blockers and has programs in various stages of development based on the Halneuron® platform. WEX has conducted late‐stage multinational clinical trials in cancer pain and chemotherapy‐induced neuropathic pain. WEX is a wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing, sale of, and investment in products and assets which fall into three core categories – nutraceuticals, pharmaceuticals and agriculture‐related. CKLS is a member of the CK Hutchison Group. For additional information, please visit www.ck‐lifesciences.com.
No comments:
Post a Comment